To Evaluate the Preliminary Efficacy and Safety/Tolerability of VRT106 Combined with Radiotherapy in Adult Patients with DMG/DIPG
Eligibility
Sex
ALL
Min age
18 Years
Max age
75 Years
Healthy volunteers
No
Inclusion Criteria:
* Voluntary signing of the Informed Consent Form (ICF), indicating understanding of the study and willingness and ability to comply with all study procedures.
* Male or female adults aged 18 to 75 years at the time of signing the ICF.
* Histologically or cytologically confirmed H3 K27-altered diffuse midline glioma (DMG), or a diagnosis of DIPG based on brain contrast-enhanced MRI: tumor originating in the pons, occupying \>50% of the pons volume, with diffuse brainstem enlargement.
* Karnofsky Performance Status (KPS) score ≥ 60.
* Expected survival time ≥ 3 months.
Exclusion Criteria:
* Individuals with extracranial metastases.
* Presence of spinal cord tumors or evidence of leptomeningeal disease dissemination.
* Active hemorrhage detected on cranial MRI scan prior to enrollment.
* Inability to undergo cranial MRI scanning (e.g., due to contraindications or incompatible implants).
* Prior receipt of oncolytic virus therapy or other gene therapy agents.
Primary outcome measure(s)
Disease Control Rate — About 2 years Evaluations will be performed at 6 weeks (± 3 days) following the completion of radiotherapy, subsequently every 9 weeks (± 7 days) during the first year of treatment, and then every 12 weeks (± 7 days) thereafter.
Trial sites (1)
Facility
City
Region
Status
Sun Yat-sen University Cancer Center
Guangzhou
Guangdong
Recruiting
More Guangzhou Virotech Pharmaceutical Co., Ltd. trials in China
This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.
We use cookies to analyse site traffic and improve your experience. With your consent, we may also use cookies for advertising. You can change your choice at any time on our Cookie Policy page. See also our Privacy Policy.